U.S. Markets closed

SPDR S&P Telecom ETF (XTL)


NYSEArca - NYSEArca Delayed Price. Currency in USD
Add to watchlist
71.02+0.24 (+0.34%)
At close: 8:00PM EDT
People also watch
XSWXHEXTNXHSXSD
Interactive chart
Previous Close70.78
Open70.61
Bid66.73 x 300
Ask0.00 x
Day's Range70.58 - 71.34
52 Week Range54.61 - 74.28
Volume6,093
Avg. Volume15,145
Net Assets77.96M
NAV70.87
PE Ratio (TTM)N/A
Yield1.15%
YTD Return2.29%
Beta (3y)1.02
Expense Ratio (net)0.35%
Inception Date2011-01-26
Trade prices are not sourced from all markets
  • PR Newswirelast month

    XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that Mr. Alex Rabinovich has been appointed as a member of the Company's board of directors. Mr. Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.

  • PR Newswire2 months ago

    XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome

    RAANANA, Israel, April 5, 2017 /PRNewswire/ -- Additional data shows a statistically significant effect in the gene expression of two additional genes that have a role in the pathogenesis of Sj ö gren ...

  • PR Newswire2 months ago

    XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its private offering of securities for proceeds of $2.8 million. In connection with the offering, announced previously on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").